(Q38175799)

English

Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis

scientific article published on 04 January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

0 references

Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

rheumatoid arthritis

0 references

systematic review

1 reference

based on heuristic

inferred from title

author name string

Xingming Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Fuxiang Liang

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Xiaoxue Yin

3

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Xiaojuan Xiao

4

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Peiyu Shi

5

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Dang Wei

6

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Liang Yao

7

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Qi Wang

8

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Yaolong Chen

9

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

4 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Clinical Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

165-173

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2452-7

21 January 2018

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2452-7

21 January 2018

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2452-7

21 January 2018

Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2452-7

21 January 2018

Treating rheumatoid arthritis to target: recommendations of an international task force

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2452-7

21 January 2018

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2452-7

21 January 2018

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2452-7

21 January 2018

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

1 reference

https://pubmed.ncbi.nlm.nih.gov/24389749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

1 reference

https://pubmed.ncbi.nlm.nih.gov/24389749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/24389749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/24389749

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10067-013-2452-7

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38175799&oldid=2150800843"